Centers for Medicare & Medicaid Services (CMS) grant transitional pass-through (TPT) payment for Stryker's SpineJack® System
Over 700,000 patients in the U.S. suffer from osteoporotic compression fractures each year.
KALAMAZOO, Michigan, USA, Dec. 4, 2020 /PRNewswire/ --The Centers for Medicare & Medicaid Services (CMS) announced the SpineJack implantable fracture reduction system qualified for the Transitional Pass-Through (TPT) payment as part of the 2021 Medicare Hospital Outpatient Prospective Payment System. The SpineJack System now becomes one of only 11 medical devices to receive TPT status since 2016.
The TPT payment provides additional payments for new medical devices that demonstrate a substantial clinical improvement over existing technologies. The TPT payment will be effective on Jan. 1, 2021. The TPT payment will provide outpatient facilities with incremental Medicare payment for the SpineJack System for up to three years.
This announcement comes just over two months after CMS awarded the SpineJack System the New Technology Add-on Payment (NTAP), which provides additional payment in the hospital inpatient setting.
"The CMS Transitional Pass-Through payment determination is a monumental step in providing a superior device technology in the treatment of osteoporotic vertebral compression fractures," said Greg Siller, Vice President and General Manager of Stryker's Interventional Spine business. "Due to the SpineJack System receiving both NTAP and TPT payment, physicians and administrators no longer have to make a decision between care and cost. We remain committed to offering innovative Interventional Spine solutions and working with our customers to improve patients' lives."
Over 700,000 patients in the U.S. suffer from osteoporotic compression fractures each year. Changing the course of treatment for vertebral compression fractures (VCF), the SpineJack System comprehensively addresses reduction, fixation and restoration of these fractures. Vertebral augmentation procedures—such as balloon kyphoplasty (BKP)—have been shown to reduce mortality by up to 55% compared to non-surgical management.
Also to be discovered
Great article about Abivax : what makes it a unique candidate to treat Covid-19
In addition to its exciting results in ulcerative colitis...
Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests
Abivax, the French biotech embarking on tests of its lead experimental medicine for Covid-19, has turned away several suitors in recent months.